MALDI-TOF Mass Spectrometry for Early HCC Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current screening methods for hepatocellular carcinoma (HCC) are inadequate, with serum alpha-fetoprotein (AFP) testing lacking sensitivity and specificity, and ultrasound variability, making early detection challenging, especially in high-risk populations, and existing biomarkers do not provide sufficient benefit for early-stage detection.
Innovation Solution
A serum-based test using Matrix Assisted Laser Desorption and Ionization-Time of Flight (MALDI-TOF) mass spectrometry with a classifier configured as a combination of filtered mini-classifiers, employing deep MALDI technique and regularized combination methods to analyze blood samples for early detection of HCC in high-risk patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If serum AFP testing is used for HCC screening, then the screening process is simple and inexpensive, but the sensitivity and specificity are insufficient for early detection
Solution Approach 1:
The patent segments the complex proteome into specific protein features that can be individually analyzed by mass spectrometry. By dividing the overall protein profile into discrete measurable features, the system achieves high detection accuracy while maintaining a manageable testing process through automated analysis
Solution Approach 2:
The patent introduces mass spectrometry as an intermediary technology between simple serum testing and complex tissue biopsy. This intermediary approach enables non-invasive detection with high precision by analyzing protein patterns in blood serum without requiring direct tissue sampling
2Reliability
If ultrasound screening is performed for HCC detection, then early stage tumors can be detected, but inter- and intra-operator variability and machine variability reduce reliability
Solution Approach 1:
The mass spectrometry system performs automated analysis of serum protein patterns without requiring operator interpretation. The instrument autonomously measures protein features and generates diagnostic results, eliminating operator dependency and ensuring consistent, reproducible screening across different patients and time points
Solution Approach 2:
The patent replaces the mechanical ultrasound imaging system with a mass spectrometry-based biochemical analysis system. This substitution transitions from visual interpretation of images to automated measurement of molecular signatures, thereby eliminating operator variability and machine setting dependencies
3Measurement precision
If CT scans with contrast are used to detect smaller tumors, then detection sensitivity improves, but the complexity and cost of the screening protocol increases
Solution Approach 1:
The patent extracts diagnostic information directly from serum proteins before tumor formation or growth becomes detectable by imaging. By analyzing the biochemical signature in blood, the system detects HCC at a molecular level, extracting early disease signals that precede anatomical changes visible on CT scans
Solution Approach 2:
Instead of using imaging to detect structural changes in tumors, the patent inverts the approach by using mass spectrometry to detect biochemical changes in serum proteins. This inverse strategy detects molecular alterations that occur earlier in disease progression than anatomical changes, achieving high sensitivity without complex imaging protocols
4Reliability
If additional imaging studies and frequent monitoring are recommended for patients with rising AFP levels, then early HCC may be detected, but the screening burden and cost increase
Solution Approach 1:
The mass spectrometry assay performs preliminary detection of HCC by analyzing serum protein patterns before clinical symptoms or tumor growth occur. By identifying molecular signatures of early disease, the system enables single-point screening that prevents the need for repeated monitoring and additional imaging studies
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves improved sensitivity and specificity in detecting early-stage HCC, allowing for timely intervention and potentially increasing 5-year survival rates, as it accurately identifies patients likely to have HCC or not, guiding appropriate treatment.
Implementation Method 1
performing MALDI-TOF mass spectrometry on a blood-based sample obtained from the patient by subjecting the sample to at least 100,000 laser shots
Implementation Method 2
Matrix Assisted Laser Desorption and Ionization-Time of Flight (MALDI-TOF) mass spectrometry
Data Source
AI summary
Hepatocellular carcinoma (HCC) is detected in a patient with liver disease. Mass spectrometry data from a blood-based sample from the patient is compared to a reference set of mass-spectrometry data from a multitude of other patients with liver disease, including patients with and without HCC, in a general purpose computer configured as a classifier. The classifier generates a class label, such as HCC or No HCC, for the test sample. A laboratory system for early detection of HCC in patients with liver disease is also disclosed. Alternative testing strategies using AFP measurement and a reference set for classification in the form of class-labeled mass spectral data from blood-based samples of lung cancer patients are also described, including multi-stage testing.